Celltrion unveils promising results for four-target obesity drug

What happened: Celltrion presented preclinical results for CT-G32/SCO-940, a quadruple agonist obesity drug candidate, with Japanese partner SCOHIA PHARMA at TIDES Europe in Amsterdam. Key numbers: Targets four pathways: GLP-1, GIP, glucagon and amylin. Why it matters: In obese rats the candidate produced greater weight loss than retatrutide at the same dose and a smaller reduction in lean body mass. Celltrion aims to differentiate it on body composition and metabolic health. Findings remain preclinical.

Celltrion presented preclinical results for CT-G32/SCO-940, a quadruple agonist obesity drug candidate, with Japanese partner SCOHIA PHARMA at TIDES Europe in Amsterdam.

In obese rats the candidate produced greater weight loss than retatrutide at the same dose and a smaller reduction in lean body mass. Celltrion aims to differentiate it on body composition and metabolic health. Findings remain preclinical.